AstraZenecas Combination Therapy Meets Goal in Prostate Cancer Study
| CTMX Stock | USD 0.87 0.07 7.45% |
Slightly above 62% of CytomX Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading CytomX Therapeutics stock suggests that many investors are alarmed at this time. CytomX Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CytomX Therapeutics' earnings reports, geopolitical events, and overall market trends.
CytomX |
Data from a late-stage study shows that treatment with a three-drug combo involving AZNs Truqap benefits patients with an aggressive form of prostate cancer.
Read at zacks.com
 |
CytomX Therapeutics Fundamental Analysis
We analyze CytomX Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
CytomX Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
CytomX Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CytomX Therapeutics stock to make a market-neutral strategy. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics with similar companies.
Peers
CytomX Therapeutics Related Equities
| TIL | Instil Bio | 5.30 | ||||
| ACHL | Achilles Therapeutics | 2.21 | ||||
| NXTC | NextCure | 1.25 | ||||
| NUVB | Nuvation Bio | 1.63 | ||||
| SPRO | Spero Therapeutics | 2.27 | ||||
| ASMB | Assembly Biosciences | 3.73 |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.